Inter-relationship between diabetes and breast cancer biomarkers


Author(s): Jinseog Kim, Rabindra Nath Das, Youngjo Lee

The glucose metabolisms and serum lipid are assumed as possible intermediary mechanisms in linking between breast cancer (BC) and obesity. The current report examines the associations between diabetes mellitus (DM) markers (glucose and insulin) and BC markers (monocyte chemoattractant protein-1 (MCP-1), resistin, adiponectin, leptin). Glucose model shows that mean glucose levels are higher for breast cancer women (P=0.0222) then normal. Mean glucose levels are positively associated with leptin (P<0.0001) and homeostasis model assessment score insulin resistance (HOMA-IR) (P<0.0001), while they are negatively associated with interaction effects HOMA-IR*leptin (P<0.0001) and leptin*adiponectin (P=0.0883). On the other hand, variance of glucose levels is positively associated with HOMA-IR (P<0.0001) and resistin (P=0.0218), while it is negatively associated with leptin (P<0.0001), MCP-1 (P=0.0115). Insulin model shows that mean insulin levels are positively associated with HOM-IR (P<0.0001), leptin (P=0.0009), age*MCP-1 (P=0.0909), glucose*adiponectin (P=0.0424), glucose*resistin (P<0.0001), HOMA-IR*MCP-1 (P<0.0001), while they are negatively associated with MCP-1 (P=0.0264), resistin (P<0.0001), adiponectin(P=0.0783), glucose*HOMA-IR (P<0.0001), leptin*adiponectin (P=0.0713). Variance of insulin levels is higher for breast cancer women (P=0.0003) than normal. Again, it is positively associated with MCP-1 (P=0.0014), HOMA-IR (P<0.0001), while it is negatively associated with leptin (P=0.0828) and glucose*MCP-1 (P=0.0003). Many more relationships between BC and DM markers are also reported in the current article. It is concluded that both DM and BC markers have very complex closely interlinked relationships.

Share this article

Editors List

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)